Edition:
United Kingdom

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

21.70USD
18 Jan 2018
Change (% chg)

$-0.58 (-2.60%)
Prev Close
$22.28
Open
$22.19
Day's High
$22.20
Day's Low
$21.00
Volume
490,421
Avg. Vol
687,112
52-wk High
$55.28
52-wk Low
$19.00

Chart for

About

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $3,479.97
Shares Outstanding(Mil.): 97.18
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Mallinckrodt Will Sell Recothrom, Preveleak To Baxter for $185 Mln

* MALLINCKRODT - TOTAL DEAL CONSIDERATION OF $185 MILLION, WITH $153 MILLION UPFRONT, INCLUDING EXISTING INVENTORY, REMAINDER IN POTENTIAL MILESTONE PAYMENTS

08 Jan 2018

BRIEF-Mallinckrodt Unit Borrowed $900 Mln Under Revolving Credit Facility

* MALLINCKRODT PLC SAYS ON DEC 29 UNIT OF CO BORROWED $900 MILLION AS A REVOLVING LOAN UNDER THE REVOLVING CREDIT FACILITY -SEC FILING

05 Jan 2018

BRIEF-Mallinckrodt Completes Stannsoporfin New Drug Application Filing

* MALLINCKRODT COMPLETES STANNSOPORFIN NEW DRUG APPLICATION FILING Source text for Eikon: Further company coverage:

04 Jan 2018

Mallinckrodt to buy Sucampo for about $840 million

Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million (£628.8 million) to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.

26 Dec 2017

Mallinckrodt to buy Sucampo for about $840 million

Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.

26 Dec 2017

UPDATE 2-Mallinckrodt to buy Sucampo for about $840 mln

* Deal for $18/share, a premium of about 6 pct to Friday close

26 Dec 2017

BRIEF-Sucampo Pharma Says If Merger Agreement Terminated, Co Agreed To Pay Mallinckrodt Fee Of $44 Million

* SUCAMPO PHARMACEUTICALS SAYS IF MERGER AGREEMENT TERMINATED UNDER CERTAIN CIRCUMSTANCES, CO AGREED TO PAY MALLINCKRODT FEE OF $44 MILLION - SEC FILING Source text : (http://bit.ly/2BUtNpK) Further company coverage:

26 Dec 2017

BRIEF-Mallinckrodt To Buy Sucampo Pharmaceuticals For About $1.2 Bln

* MALLINCKRODT TO ACQUIRE SUCAMPO PHARMACEUTICALS FOR APPROXIMATELY $1.2 BILLION

26 Dec 2017

Mallinckrodt to buy Sucampo Pharmaceuticals for about $1.2 bln

Dec 26 Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc in a deal valued at about $1.2 billion to gain access to its constipation drug, Amitiza.

26 Dec 2017

BRIEF-Mallinckrodt Says TCJA Is Expected To Have A Neutral To Slightly Positive Impact On Adj Tax Expense Of Co

* MALLINCKRODT PLC SAYS TCJA IS EXPECTED TO HAVE A NEUTRAL TO SLIGHTLY POSITIVE IMPACT ON NON-GAAP ADJUSTED TAX EXPENSE OF CO - SEC FILING

22 Dec 2017

Competitors

  Price Chg
Meda AB (MEDAa.ST) -- --
Merck KGaA (MRCG.DE) €90.12 --
AB Science SA (ABS.PA) €9.01 --

Earnings vs. Estimates